Amid the COVID-19 pandemic that is reshaping the world and in particular the healthcare industry, life sciences investments in 2020 have showed an upbeat picture as funding to healthcare companies was up 4% quarter-over-quarter in Q1 2020, reaching an amount of US$14.6 billion. While the healthcare sector starts to emerge from the crisis and the outbreak is leading to policy changes such as the liberalization of telemedicine services, the newly effective CFIUS implementation regulations have expanded its jurisdiction and more FDI screening rules will soon come to effect across Europe, all presenting unique challenges to cross-border transactions. Finding ways to navigate through the turmoil has become a critical subject to global investors.
Moderated by Morrison & Foerster partner Chuan Sun, who has more than 16 years of experience in China and the U.S., this panel features leading experts and senior attorneys from Morrison & Foerster. Senior Advisor Joe Benkert, former leading civilian official in the Department of Defense for CFIUS and related national security matters, will discuss the strategic and practical importance for cross-border transactions of the newly effective rules expanding CFIUS coverage, thinking ahead about CFIUS early in a transaction’s life cycle, and navigating key changes to the CFIUS review process; partner Bethany Hills, a well-recognized practitioner with deep FDA regulatory experience, will dive into key FDA regulatory updates including the recent regulatory relief that will present new investment opportunities and give rise to new digital health business models; and partner Wolfgang Schoenig, who has substantial experience in life sciences transactions, will share his insights on opportunities and challenges brought by newly revised German foreign investment rules as well as other COVID-induced legislation and trends in the life sciences industry.
Visit ChinaBio Partnering Forum for more details.